This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: DG News Cardiology
Author(s): Yuting P. Chiang,

CHICAGO -- September 30, 3014 -- Among patients aged 50 to 69 years who underwent aortic valve replacement with bioprosthetic or mechanical prosthetic valves, there was no significant difference in 15-year survival or stroke, although patients in the bioprosthetic valve group had a greater likelihood of re-operation but a lower likelihood of major bleeding.

The findings are published in the October 1 issue of JAMA.

In older patients, bioprosthetic valves pose a low lifetime risk of reoperation for structural degeneration and avoid many of the complications associated with mechanical prostheses. Bioprosthetic valves are therefore recommended in patients aged older than 70 years. However, the optimal prosthesis type for younger patients is less clear.

Yuting P. Chiang, Mount Sinai Hospital, New York, New York, and colleagues used a state-wide administrative database to quantify differences in long-term survival, stroke, re-operation, and major bleeding episodes after aortic valve replacement according to prosthesis type.

Source: Annals of Thoracic Surgery
Author(s): Mark D. Plunkett, Brian A. Harvey, Lazaros K. Kochilas, Jeremiah S. Menk, James D. St. Louis

Optimal management of a VSD at the time of coarctation repair is controversial.  The retrospective review of the Pediatric Cardiac Care Consortium 1982-2007 evaluated outcomes for 2,022 patients.    The presence of a VSD increased operative mortality 4-fold to 8.3%.  Patients underwent coarct repair and VSD closure at an older age (87 days) than for coarct repair and PA banding (22 days).  Discharge mortality was about 9% for each group.  Hospital mortality for patients who underwent coarct repair but no surgical VSD management had a discharge mortality of 7.9%. 

Source: Annals of Thoracic Surgery
Author(s): Alexander Iribarne, Helena Chang, John H. Alexander, A. Marc Gillinov, Ellen Moquete, John D. Puskas, Emilia Bagiella, Michael A. Acker, Mary Lou Mayer, T. Bruce Ferguson, Sandra Burks, Louis P. Perrault, Stacey Welsh, Karen C. Johnston, Mandy Murphy, Joseph J. DeRose, Alexis Neill, Edlira Dobrev, Kim T. Baio, Wendy Taddei-Peters, Alan J. Moskowitz, Patrick T. O’Gara

This study assessed risk factors, frequency, and timing associated with readmission after cardiac surgery using data for 5,158 pts from 10 participating centers.  The overall readmission rate was 19%, and was highest for combined CABG and valve operations.  Readmissions were more common in the first 30 days after discharge (80% of total), and were most often due to fluid overload, infection, and arrhythmia.  Baseline conditions associated with readmission were female sex, AKI, COPD, diabetes, anemia, and prolonged operating time.

Source: Annals of Thoracic Surgery
Author(s): Jeffrey L. Port, Bhupesh Parashar, Nonso Osakwe, Abu Nasar, Paul C. Lee, Subroto Paul, Brendon M. Stiles, Nasser K. Altorki

Using a single institution database, the authors propensity score matched patients receiving wedge resection, wedge resection plus brachytherapy, or SBRT for early stage NSCLC.  Survival was assessed at a median of 35 mos.  Overall recurrence was higher for SBRT vs wedge (30% vs 9%), and recurrence-free and disease-free survival were better after wedge than SBRT.  Male sex and SBRT were significant predictors of mortality and recurrence.

Source: JAMA
Author(s): Yuting P. Chiang; Joanna Chikwe; Alan J. Moskowitz; Shinobu Itagaki; David H. Adams; Natalia N. Egorova

The New York State database was used to perform a retrospective analysis of outcomes for isolated AVR comparing bioprosthetic to mechanical valves.  Propensity matching was used to create 1001 patient pairs.  Survival  and stroke rates were similar between the groups at an average of 10.8 years follow-up.  The cumulative incidence of reoperation  was higher in the bioprosthetic group (12.1% vs 6.9%) but the cumulative incidence of major bleeding was lower in that group (6.6% vs 13.0%). 

Source: JAMA
Author(s): Tiziana Bove and others

This randomized double-blind multicenter study involving 667 pts evaluated the utility of IV fenoldopam in reducing the rate of renal replacement therapy for patients undergoing cardiac surgery who exhibit postoperative acute kidney injury.  Fenoldopam did not importantly reduce the need for renal replacement therapy or 30 day mortality.  Its use was asssociated with an increase in postoperative hypotension.

Source: DG News Cardiology
Author(s): Walter Alexander

WASHINGTON D.C. -- September 16, 2014 -- Use of a dual-filter cerebral protection system reduces the number and volume of cerebral lesions in patients with severe aortic stenosis undergoing transaortic valve replacement (TAVR), according to prospective research presented at the 2014 Transcatheter Cardiovascular Therapeutics meeting (TCT).

“In patients with severe aortic stenosis who are at increased surgical risk, the use of [a] dual-filter cerebral protection system during TAVR significantly reduces the number and volume of cerebral lesions as determined by DW-MRI [diffusion-weighted magnetic resonance imaging] subtraction at 2 and 7 days after TAVR,” explained presenter Axel Linke, MD, University of Leipzig Heart Center, Leipzig, Germany, speaking here at a plenary session on September 13.

“Although results with TAVR have improved considerably over the last decade, stroke remains a major issue, and increases mortality by threefold,” Dr. Linke noted. He said also that neuro-imaging studies are revealing ischaemic brain lesions in more than two-thirds of these patients. “We know that those lesions are associated with a poorer neurocognitive outcome,” he added.

Source: Journal of Thoracic Oncology
Author(s): Cressman, Sonya and others

Costs of lung cancer screening were determined for individuals with a 2% or greater risk of lung cancer over 3 years for 2059 subjects participating in the Pan-Canadian Early Detection of Lung Cancer Study.  During the first 18 mos of screening the per-person cost was $453.  Surgical therapy cost $33,344 over 2 years compared to costs of treating advanced stage cancers of $47,792. 

Source: Journal of Thoracic Oncology
Author(s): den Hengst, Willem A.; Hendriks, Jeroen M.H.; Balduyck, Bram; Rodrigus, Inez; Vermorken, Jan B.; Lardon, Filip; Versteegh, Michel I.M.; Braun, Jerry; Gelderblom, Hans; Schramel, Franz M.N.H.; Van Boven, Wim-Jan; Van Putte, Bart P.; Birim, Özcan; Maat, Alexander P.W.M.; Van Schil, Paul E.Y.

This phase II trial evaluated outcomes of isolated lung perfusion with Melphalan and complete surgical resection for pulmonary metastases from colorectal cancer or sarcoma in 50 pts.  Surgical mortality was 0%, but morbidity (primarily grade 3 or 4 pulmonary morbidity) was 44%.  30 patients suffered local recurrence.  3-year survival was 57% and recurrence-free survival was 36%. 

Source: Journal of Thoracic Oncology
Author(s): Deppen, Stephen A.; Blume, Jeffrey D.; Aldrich, Melinda C.; Fletcher, Sarah A.; Massion, Pierre P.; Walker, Ronald C.; Chen, Heidi C.; Speroff, Theodore; Degesys, Catherine A.; Pinkerman, Rhonda; Lambright, Eric S.; Nesbitt, Jonathan C.; Putnam, Joe B.; Grogan, Eric L.

A model for predicting lung cancer in patients with suspicious lung nodules (TREAT) was developed using single institutional data (Vanderbilt), validated using data from another institution, and compared to the Mayo Clinic predictive model.  The model accuracy was 87% in the development cohort and 89% in the validation cohort, compared to 80% in the Mayo Clinic model.